Study Suggests Covis Pharma’s Preterm Birth Drug Carries Cancer Risk

The main substance in Covis Pharma’s premature birth drug Makena — a synthetic hormone known as 17α-hydroxyprogesterone caproate (17-OHPC) — has been linked with an increased risk of cancer in offspring exposed to the treatment in the womb, says a new study.
Source: Drug Industry Daily